MINT-CELECOXIB CAPSULE

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

CELECOXIB

Saatavilla:

MINT PHARMACEUTICALS INC

ATC-koodi:

M01AH01

INN (Kansainvälinen yleisnimi):

CELECOXIB

Annos:

100MG

Lääkemuoto:

CAPSULE

Koostumus:

CELECOXIB 100MG

Antoreitti:

ORAL

Kpl paketissa:

30/1000

Prescription tyyppi:

Prescription

Terapeuttinen alue:

CYCLOOXYGENASE-2 (COX-2) INHIBITORS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0137043001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2014-11-17

Valmisteyhteenveto

_MINT-CELECOXIB (celecoxib) _
_Page 1 of 57 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-CELECOXIB
Celecoxib Capsules
Capsules, 100 mg and 200 mg, for oral use
Non-steroidal Anti-Inflammatory Drug (NSAID)
Mint Pharmaceuticals Inc.
6575 Davand Drive
Mississauga, Ontario
L5T 2M3
Date of Initial Authorization:
November 17, 2014
Date of Revision:
September 23, 2022
Submission Control No: 263511
_MINT-CELECOXIB (celecoxib) _
_Page 2 of 57 _
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
09/2022
7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests, Pregnancy
09/2022
7 WARNINGS AND PRECAUTIONS, Skin, _Serious skin reactions_
09/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant women
09/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED .
RECENT MAJOR LABEL CHANGES
......................................................................................................2
TABLE OF CONTENTS
........................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................................4
1
INDICATIONS
........................................................................................................................4
1.1
Pediatrics
.....................................................................................................................4
1.2
Geriatrics
.....................................................................................................................4
2
CONTRAINDICATIONS
...........................................................................................................5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
......................................................................6
4
DOSAGE AND ADMINISTRATION
...........................................................................................7
4.1
Dosing Considerations
...........